At a $794M market cap with a Forward P/E of 13, ACVA screens optically inexpensive, but this is not a clean value story. The company is operating with a negative EPS of -62.3, an operating margin of -15.40%, and a deeply distressed Altman Z-Score of 0.8, which signals elevated financial risk. A Piotroski F-Score of 5 suggests middling fundamentals rather than a turnaround in full swing. The market is pricing in improvement via the forward multiple, but the balance sheet stress and negative profitability metrics suggest this is a speculative recovery play, not a proven compounder.